$Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT$

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT

Background: Children with juvenile idiopathic arthritis (JIA) are at risk of uveitis. The role of adalimumab (Humira®; AbbVie Inc., Ludwigshafen, Germany) in the management of uveitis in children needs to be determined. Objective: To compare the efficacy, safety and cost-effectiveness of adalimumab...

Full description

Bibliographic Details
Main Authors:	Athimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, Dyfrig A Hughes, Andrew McKay, Anna Rosala-Hallas, Paula R Williamson, Ben Hardwick, Helen Hickey, Naomi Rainford, Graeme Hickey, Ruwanthi Kolamunnage-Dona, Giovanna Culeddu, Catrin Plumpton, Eifiona Wood, Sandrine Compeyrot-Lacassagne, Patricia Woo, Clive Edelsten, Michael W Beresford
Format:	Article
Language:	English
Published:	NIHR Journals Library 2019-04-01
Series:	Health Technology Assessment
Subjects:	ADALIMUMAB JUVENILE IDIOPATHIC ARTHRITIS RANDOMISED CONTROLLED TRIAL METHOTREXATE OPHTHALMOLOGY PAEDIATRIC RHEUMATOLOGY SAFETY UVEITIS
Online Access:	https://doi.org/10.3310/hta23150

Similar Items

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
by: William D. Renton, et al.
Published: (2019-10-01)

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
by: Shubhadeep Sinha, et al.
Published: (2020-06-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Adalimumab
by: Nilgun Atakan
Published: (2022-04-01)

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
by: Nisha R. Acharya, et al.
Published: (2020-10-01)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Criptosporidiose em paciente com espondilite anquilosante usando adalimumabe Cryptosporidiosis in a patient with ankylosing spondylitis treated with adalimumab
by: Fernando Augusto Chiuchetta
Published: (2010-06-01)

Diffuse large B-cell lymphoma that develops after adalimumab using adalimumab in a patient with psoriasis
by: Esra Yıldırım Bay, et al.
Published: (2021-06-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Subcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica
by: Nefyn H Williams, et al.
Published: (2017-10-01)

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
by: DA Al-Julandani, et al.
Published: (2023-03-01)

Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)
by: Nefyn H. Williams, et al.
Published: (2018-07-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
by: Savas Yayli, et al.
Published: (2013-11-01)

Relapsing Polychondritis: A Case Report of the Use of Adalimumab in Steroid Dependent Disease
by: Taylor Dimmerling, et al.
Published: (2023-05-01)

First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
by: E L Luchichina, et al.
Published: (2008-10-01)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
by: Fotiadou C, et al.
Published: (2016-10-01)

Invasive Cryptococcosis and Adalimumab Treatment
by: Juan P. Horcajada, et al.
Published: (2007-06-01)

The effect of adalimumab on the vasculature in psoriatic skin lesions
by: S. C. A. Hanssen, et al.
Published: (2019-04-01)

Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment
by: T.V. Marushko, et al.
Published: (2023-03-01)

Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Brain Injury
by: Mehmet Yalçın Günal, et al.
Published: (2019-10-01)

Group A Streptococcus Brain Abscess in a Patient on Adalimumab Therapy
by: Ryan Carroll, et al.
Published: (2019-07-01)

Adalimumab Monotherapy in the Treatment of Idiopathic Multifocal Choroiditis: A Case Report
by: Arash Maleki, et al.
Published: (2022-11-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
by: Elena Yurievna Loginova, et al.
Published: (2010-06-01)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
by: Glenn Harvin, et al.
Published: (2016-05-01)

Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)
by: Ayman Elgendi, et al.
Published: (2015-01-01)

Treatment of granulomatous rosacea with adalimumab
by: Ryan C. Saal, BS, et al.
Published: (2023-10-01)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023-04-01)

The effectiveness of adalimumab treatment for non-infectious uveitis
by: Eiichi Hasegawa, et al.
Published: (2019-04-01)

Profile of adalimumab and its potential in the treatment of uveitis
by: Balevic SJ, et al.
Published: (2016-09-01)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
by: Keijiro Numa, et al.
Published: (2023-10-01)

Adalimumab in Treating Refractory Livedoid Vasculopathy
by: Xiao-Wen Huang, et al.
Published: (2022-04-01)

ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)

Lethality of patients with rheumatoid arthritis depending on adalimumab administration: imitation modeling
by: D V Goryachev, et al.
Published: (2009-10-01)

Multiple COVID reinfections in a vaccinated psoriatic patient receiving adalimumab
by: Omid Zargari, et al.
Published: (2022-11-01)

Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine
by: Rafael León-Montañes, et al.
Published: (2013-03-01)

Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis
by: Ione C.P. Pereira, et al.
Published: (2018-06-01)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
by: Dubravka Bosnić, et al.
Published: (2016-12-01)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
by: Aikaterini Kyriakou, et al.
Published: (2018-10-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)